|
|
 |
|
Total Number of Holdings (excluding cash): 50
| AbbVie Inc. |
ABBV |
00287Y109 |
Pharmaceuticals |
297,675 |
$78,687,409.50 |
7.31% |
| Eli Lilly and Company |
LLY |
532457108 |
Pharmaceuticals |
65,988 |
$78,094,158.48 |
7.25% |
| Johnson & Johnson |
JNJ |
478160104 |
Pharmaceuticals |
287,115 |
$77,871,330.30 |
7.23% |
| Merck & Co., Inc. |
MRK |
58933Y105 |
Pharmaceuticals |
516,579 |
$76,856,623.62 |
7.14% |
| Pfizer Inc. |
PFE |
717081103 |
Pharmaceuticals |
2,682,001 |
$76,892,968.67 |
7.14% |
| Viatris Inc. |
VTRS |
92556V106 |
Pharmaceuticals |
2,311,622 |
$41,216,220.26 |
3.83% |
| Biogen Inc. |
BIIB |
09062X103 |
Biotechnology |
176,159 |
$40,093,788.40 |
3.72% |
| Gilead Sciences, Inc. |
GILD |
375558103 |
Pharmaceuticals |
260,795 |
$39,361,789.35 |
3.66% |
| Incyte Corporation |
INCY |
45337C102 |
Biotechnology |
306,274 |
$37,944,285.86 |
3.52% |
| Regeneron Pharmaceuticals, Inc. |
REGN |
75886F107 |
Biotechnology |
47,761 |
$37,637,578.44 |
3.50% |
| Vertex Pharmaceuticals Incorporated |
VRTX |
92532F100 |
Pharmaceuticals |
70,089 |
$36,880,130.91 |
3.43% |
| Amgen Inc. |
AMGN |
031162100 |
Pharmaceuticals |
88,780 |
$36,809,075.80 |
3.42% |
| Bristol-Myers Squibb Company |
BMY |
110122108 |
Pharmaceuticals |
571,245 |
$35,908,460.70 |
3.34% |
| Zoetis Inc. |
ZTS |
98978V103 |
Pharmaceuticals |
495,005 |
$35,170,105.25 |
3.27% |
| United Therapeutics Corporation |
UTHR |
91307C102 |
Pharmaceuticals |
66,382 |
$31,561,321.90 |
2.93% |
| Jazz Pharmaceuticals Plc |
JAZZ |
G50871105 |
Pharmaceuticals |
121,332 |
$28,870,949.40 |
2.68% |
| Exelixis, Inc. |
EXEL |
30161Q104 |
Biotechnology |
425,130 |
$24,725,560.80 |
2.30% |
| Illumina, Inc. |
ILMN |
452327109 |
Biotechnology |
88,146 |
$23,799,420.00 |
2.21% |
| Halozyme Therapeutics, Inc. |
HALO |
40637H109 |
Biotechnology |
153,220 |
$17,451,758.00 |
1.62% |
| Medpace Holdings, Inc. |
MEDP |
58506Q109 |
Biotechnology |
26,295 |
$16,273,449.60 |
1.51% |
| Alnylam Pharmaceuticals, Inc. |
ALNY |
02043Q107 |
Biotechnology |
54,668 |
$13,992,821.28 |
1.30% |
| BioMarin Pharmaceutical Inc. |
BMRN |
09061G101 |
Pharmaceuticals |
223,501 |
$13,468,170.26 |
1.25% |
| Neurocrine Biosciences, Inc. |
NBIX |
64125C109 |
Biotechnology |
90,177 |
$12,480,496.80 |
1.16% |
| Elanco Animal Health Incorporated |
ELAN |
28414H103 |
Pharmaceuticals |
547,459 |
$12,213,810.29 |
1.13% |
| Charles River Laboratories International, Inc. |
CRL |
159864107 |
Biotechnology |
36,923 |
$10,812,531.32 |
1.00% |
| Moderna, Inc. |
MRNA |
60770K107 |
Biotechnology |
37,800 |
$7,517,664.00 |
0.70% |
| 10X Genomics, Inc. (Class A) |
TXG |
88025U109 |
Biotechnology |
84,947 |
$7,280,807.37 |
0.68% |
| Iovance Biotherapeutics, Inc. |
IOVA |
462260100 |
Biotechnology |
649,317 |
$7,142,487.00 |
0.66% |
| Twist Bioscience Corporation |
TWST |
90184D100 |
Biotechnology |
38,165 |
$6,977,706.95 |
0.65% |
| Caris Life Sciences, Inc. |
CAI |
142152107 |
Biotechnology |
208,118 |
$6,655,613.64 |
0.62% |
| Adaptive Biotechnologies Corporation |
ADPT |
00650F109 |
Biotechnology |
212,879 |
$6,265,028.97 |
0.58% |
| Amneal Pharmaceuticals, Inc. |
AMRX |
03168L105 |
Pharmaceuticals |
303,659 |
$6,003,338.43 |
0.56% |
| Guardant Health, Inc. |
GH |
40131M109 |
Biotechnology |
33,360 |
$5,913,060.00 |
0.55% |
| Tango Therapeutics, Inc. |
TNGX |
87583X109 |
Biotechnology |
232,265 |
$5,788,043.80 |
0.54% |
| Ligand Pharmaceuticals Inc. (Class B) |
LGND |
53220K504 |
Biotechnology |
18,673 |
$5,630,282.96 |
0.52% |
| TG Therapeutics, Inc. |
TGTX |
88322Q108 |
Biotechnology |
97,696 |
$5,610,681.28 |
0.52% |
| Roivant Sciences Ltd. |
ROIV |
G76279101 |
Biotechnology |
153,145 |
$5,482,591.00 |
0.51% |
| Corcept Therapeutics Inc. |
CORT |
218352102 |
Pharmaceuticals |
46,802 |
$5,433,712.20 |
0.50% |
| Liquidia Technologies, Inc. |
LQDA |
53635D202 |
Biotechnology |
77,819 |
$5,325,154.17 |
0.49% |
| Krystal Biotech, Inc. |
KRYS |
501147102 |
Biotechnology |
14,763 |
$5,105,340.66 |
0.47% |
| Protagonist Therapeutics, Inc. |
PTGX |
74366E102 |
Biotechnology |
35,905 |
$5,093,483.30 |
0.47% |
| Spyre Therapeutics, Inc. |
SYRE |
00773J202 |
Biotechnology |
59,386 |
$5,088,786.34 |
0.47% |
| Kymera Therapeutics, Inc. |
KYMR |
501575104 |
Biotechnology |
44,651 |
$4,998,679.45 |
0.46% |
| Oruka Therapeutics, Inc. |
ORKA |
687604108 |
Biotechnology |
57,276 |
$4,837,530.96 |
0.45% |
| Travere Therapeutics, Inc. |
TVTX |
89422G107 |
Pharmaceuticals |
80,038 |
$4,757,458.72 |
0.44% |
| Alkermes Plc |
ALKS |
G01767105 |
Pharmaceuticals |
112,895 |
$4,611,760.75 |
0.43% |
| Dianthus Therapeutics, Inc. |
DNTH |
252828108 |
Biotechnology |
50,231 |
$4,447,955.05 |
0.41% |
| Arrowhead Pharmaceuticals, Inc. |
ARWR |
04280A100 |
Biotechnology |
64,388 |
$4,244,456.96 |
0.39% |
| Enliven Therapeutics Inc. |
ELVN |
29337E102 |
Biotechnology |
91,638 |
$4,100,800.50 |
0.38% |
| ACADIA Pharmaceuticals Inc. |
ACAD |
004225108 |
Biotechnology |
183,498 |
$3,794,738.64 |
0.35% |
| US Dollar |
$USD |
|
Other |
3,319,694 |
$3,319,694.18 |
0.31% |
Holdings are subject to change.
The holdings information set forth above for the date indicated reflects creation and redemption transactions from the prior business day and may differ from the holdings information currently available from the Fund's custodian and accounting agent. With respect to the market value of the Fund's holdings set forth above, the pricing sources are generally third party vendors. The Fund ultimately relies on pricing information provided by the Fund's accounting agent.
|
|
The information presented is not intended to constitute an investment recommendation for, or advice to, any specific person. By providing this information, First Trust is not undertaking to give advice in any fiduciary capacity within the meaning of ERISA, the Internal Revenue Code or any other regulatory framework. Financial professionals are responsible for evaluating investment risks independently and for exercising independent judgment in determining whether investments are appropriate for their clients.
|